The Top 3 Biotech Stocks to Own

July 14, 2021 www.tradewins.com Other Exciting News New Way To Grab Great Trades A brand new site has been launched that make sure you don’t miss any of the great trade ideas from our pros. At TradeWins Daily you’ll see trading ideas and valuable education from Chuck Hughes, Wendy Kirkland, Joe Duffy, Keith Harwood, Ian Cooper, and many others! Scroll back through previous articles to make sure you get every nugget. New updates posted daily with charts and tips. Click Here to Check It Out Now! Recent Articles The Top 3 Biotech Stocks to Own by Ian Cooper The Five Main Greeks by Chris Verhaegh Guaranteed Real Optioneering Winners by Chuck Hughes TradeWins Author Team     Tomorrow, you could begin doubling your account every single month starting with one letter. The letter will come from a 20-year trading professional named Ian Cooper. He says, “In 2017, following my trades you would be doubling even tripling your account some months. Let me show you how.” He will show you exactly what to do... and he’ll give you the blueprint for just $1. Get Daily Trade Alert Now About TradeWins Inside Trading Newsletter Webinars Videos Trading Strategy Options Futures Forex Day Trading Subscription Services E-Books Customer Satisfaction Survey 2020 The Top 3 Biotech Stocks to Own by Ian Cooper The meteoric rise in biotech stocks isn’t over just yet. In fact, “The outlook for 2021 for biotech is still very positive because the fundamentals are intact, innovation is continuing” and access to capital hasn’t been an issue, said Wendy Lam, a portfolio manager at Franklin Templeton., as quoted by Bloomberg. Industry success in quickly developing shots to fight the virus, “shine a light on how important the sector is for society.” Plus, there’s also incredible new innovation in genetics and technology. In fact, over the next several years, genetic testing and gene editing will help to identify and potentially cure diseases. And three, big pharmaceutical companies are buying hot biotech companies to keep their pipelines full to avoid revenue shortfalls. In short, biotech will continue to be one of the hottest opportunities to consider. Here are three of the top ones we believe could run to higher highs in the New Year. Read More   The Five Main Greeks by Chris Verhaegh Most people believe that math is scary. Usually when someone who is not familiar with trading on the market sees my notes, they see a lot of “squiggly-line math” and they get scared. I can understand that. Squiggly-line math is scary. But when I look at the math for my PULSE System, I don’t see any squiggly lines. All I see is addition, subtraction, multiplication and division. Elementary school stuff. What makes options tick? To describe the way options function experts have devised a series of five elements named with Greek letters. These are commonly referred to as “The Greeks”. Let me introduce you to them. Delta – Price I’m a NASCAR fan, so I think of Delta as speed. Delta is the amount an option will move, relative to a $1 move of the underlying issue (the stock). Read More Guaranteed Real Optioneering Winners by Chuck Hughes The first profit opportunity we will review this week is a stock purchase in NDAQ, or Nasdaq, Inc. NDAQ is a holding company that provides trading, clearing, exchange technology, regulatory, securities listing, information, and public company services. The monthly chart shows that, except for the quick pullback early last year, NDAQ has been in a steady bull trend since the chart started in 2012. The uptrend has been especially strong since last year’s low. The daily chart shows that NDAQ has a bullish pattern of higher highs and higher lows since the March low. The current pause is expected to be followed by a further advance. We recommend buying NDAQ stock at the current price level. The NDAQ dividend yield is 1.23%. Read More   www.tradewins.com                © Copyright 2021 TradeWins.com. All rights reserved. TradeWins Publishing, 22C New Leicester Hwy, #117, Asheville, NC 28806 Email: support@iss-trading.com   |   Phone: 888-233-1431   |   Fax: 888-258-4938   PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: All About Auto-Trading, TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading. 1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis. 2) TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services. 3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber. 4) You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more. 5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities. 6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown. 7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses. 8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk.

If you wish to stop receiving our emails or change your subscription options, please Manage Your Subscription
TradeWins Publishing, 528 North Country Rd., St. James, NY 11780